Keywords: solid, set, results, astrazeneca, nexium, continues, perform
Solid set of results at AstraZeneca as Nexium continues to perform well
Article | 04 February 2002
AstraZeneca says sales for the fourth quarter of 2001 increased 8% atconstant exchange rates to $4.44 billion, while operating profit was 12% higher at $1.09 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
